linjc16/ctgov huggingface dataset:
Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.

Official Title
-----------------
Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

Conditions
-----------------
Scars

Intervention / Treatment
-----------------
* Drug: Dermatix Q


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female or male patients at least 18 years of age Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc) Able and willing to provide informed consent and likely to complete all study visits All Fitzpatrick skin types will be evaluated Exclusion Criteria: Known contraindications to Dermatix or any of its components Age of scar is > 4 months Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br> | Drug: Dermatix Q<br>* Dermatix Q applied twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy |  | 1 yr | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient acceptance |  | 1 yr |
Trial Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery for Women Cystocele Repair.

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to compare with PFDI-20 questionnaire the functional outcome of laparoscopic sacrocolpopexy and vaginal mesh surgery in the treatment of symptomatic exteriorised cystocele up to 4 years after surgery. The secondary objectives of this study are the following: to compare the two techniques for anatomical results based on the clinical evaluation of patients with POP-Q. to overall quality of life assessment and expectations of patients. to compare the two techniques for the long-term safety. The evaluation will focus on the adverse effects of long-term sexual and genital symptoms, urinary and digestive functional symptoms, and chronic pelvic pain. to compare the improvement of the functional outcome assessed by PFDI-20 questionnaire (matched-analysis before versus after).

Official Title
-----------------
Randomized Controlled Trial Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery for Women Cystocele Repair: Functional and Anatomical Results at Four Years Follow-up

Conditions
-----------------
Cystocele

Intervention / Treatment
-----------------
* Other: laparoscopic sacrocolpopexy
* Other: vaginal mesh surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients included in the PROSPERE study will be included in the PROSPERE-4 study. The inclusion criterias for the PROSPERE study are: Written informed consent insured under the French social security system Exclusion Criteria: Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol Participation in another trial

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: laparoscopic sacrocolpopexy<br>laparoscopic sacrocolpopexy | Other: laparoscopic sacrocolpopexy<br> <br> |
| Other: vaginal mesh surgery<br>vaginal mesh surgery | Other: vaginal mesh surgery<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFDI-20 score | The patient-reported outcome of the intervention will be evaluated using the symptom score calculated using the PFDI-20. It is a self-administered questionnaire on symptoms of prolapse | 4 years |
Longitudinal LDL-C Studies in Black and White Families

Study Overview
=================
Brief Summary
-----------------
To longitudinally investigate multigenerational familial clustering of plasma low density lipoprotein cholesterol (LDL-C), with particular emphasis on the influences of apoE genotypes and various 'behaviors'.

Detailed Description
-----------------
BACKGROUND: Elevated concentrations of plasma low density lipoprotein cholesterol (LDL-C), a major risk factor for coronary heart disease, cluster significantly in families. This clustering has been observed in cross-sectional studies in both black and white families, but longitudinal data on the familial clustering of LDL-C are virtually nonexistent. DESIGN NARRATIVE: The longitudinal study will provide new and important information about changes in the familial low density lipoprotein cholesterol (LDL-C) correlations in black and white families from the period of shared household environments to that of separate households, using families from the Princeton Lipid Research Clinics (LRC) Prevalence (1973-75) and Family Studies (1975-76). The study will also provide important information on changes in individual LDL-C levels over the same 25 year period. The former student participants were six to 18 years of age and are now 32 to 45 years of age; their parents were (largely) 26 to 55 years of age and are now 51 to 80 years of age. Plasma LDL-C concentrations in children and adults have been shown to associate with the apolipoprotein (apo) E genotype, with obesity, and with such elective behaviors as diet, cigarette smoking, and physical activity. In the LRC Study, measurements were made of LDL-C, body habitus, elective behaviors, and the family history of cardiovascular disease (CVD). The study will obtain repeat measures of these factors, plus determine the apo E isoforms. Changes in individual LDL-C levels and in familial associations can then be assessed in association with apo E isoforms, body composition, elective behaviors, and family history of CVD. Family members share ranges of body weight, patterns of fat distribution, dietary and smoking habits, and physical activity levels. The extent to which the familial clustering of LDL-C levels is determined by apo E isoforms interacting with the similar levels of obesity, and with the similar behaviors, is not currently known.

Conditions
-----------------
Cardiovascular Diseases, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Assessment Of Anterior Chamber Configuration Changes After Phacoemulsification With Swept-Source Optical Coherence Tomography

Study Overview
=================
Brief Summary
-----------------
To assess the changes of anterior chamber angle in patients with shallow anterior chamber and normal anterior chamber after phacoemulsification and intraocular lens implantation (IOL) using anterior segment swept-source optical coherence tomography (AS-SS-OCT).To observe the 60 eyes of 60 patients in our study.

Detailed Description
-----------------
This is a prospective case-control study; 60 eyes of 60 patients who underwent cataract surgery. Based on anterior chamber depth (ACD) and gonioscopy findings, the eyes are classified into two groups, shallow anterior chamber group (30 eyes) and narrow anterior chamber group (30 eyes). AS-SS-OCT was used to measure ACD and angle parameters (angle opening distance(AOD), angle recess area(ARA), trabecular iris space area（TISA）, and trabecular iris angle (TIA). Serial changes in each group were measured before and 3 months after phacoemulsification and IOL, and the differences between the two groups were compared.

Official Title
-----------------
Assessment Of Anterior Chamber Configuration Changes After Phacoemulsification With Swept-Source Optical Coherence Tomography

Conditions
-----------------
Anterior Chamber Parameters, Phacoemulsification, Anterior Segment Swept-source Optical Coherence Tomography

Intervention / Treatment
-----------------
* Procedure: cataract surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent cataract surgery - Exclusion Criteria:patients with mild cataracts do not require surgery -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| open-angle group<br>ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope | Procedure: cataract surgery<br>* phacoemulsification and intraocular lens implantation<br>|
| narrow-angle group<br>ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope | Procedure: cataract surgery<br>* phacoemulsification and intraocular lens implantation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anterior chamber depth |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anterior chamber parameters, phacoemulsification, anterior segment swept-source optical coherence tomography
Prevalence and Characterization of Persistent Dyspnea After Hospitalization

Study Overview
=================
Brief Summary
-----------------
The investigators aim to make an overview of persistent dyspnea at the end of an hospitalization for a respiratory disease using an actual tool, the Multidisciplinary Dyspnea Profile questionnaire.

Official Title
-----------------
Prevalence and Characterization of Persistent Dyspnea After an Hospitalization for a Respiratory Disease

Conditions
-----------------
Dyspnea, Pulmonary Disease

Intervention / Treatment
-----------------
* Other: Multidisciplinary Dyspnea Profile questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years old Able to respond the questionnaire Presenting at admission a dyspnea over 3/10 on numerical analogic scale Admitted for a respiratory cause Exclusion Criteria: cognitive impairment aphasia no french-speaking person

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of persistent dyspnea in the end of an hospitalization for a a respiratory disease |  | An average of one week, until the end of the hospitalization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of persistent dyspnea using MDP |  | An average of one week, until the end of the hospitalization | 
| Outcome of patients with persistent dyspnea after hospitalization | 6 months mortality, incidence of rehospitalization | 6 months |
Audio-enhanced Analgesia in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether enhanced audio methods can be used to improve analgesia for experimental pain in healthy subjects.

Official Title
-----------------
Audio-enhanced Analgesia in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Enhanced Audio
* Behavioral: Audio


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-50 years old Healthy Exclusion Criteria: Current diagnoses of psychiatric or neurological disorders or chronic pain BDI-II score greater than 13 current or previous ear/nose/throat or hearing issues prior participation in pain studies previous advanced music training

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Music conditioning<br>Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia | Behavioral: Enhanced Audio<br> <br> Behavioral: Audio<br> <br> |
| Active Comparator: Sound<br>Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia | Behavioral: Enhanced Audio<br> <br> Behavioral: Audio<br> <br> |
| No Intervention: Calibration<br>Subjects are tested with music, sound, and silence, with no enhanced audio received | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Intensity and Unpleasantness | 0-100 Visual Analog Scales to rate subjective pain intensity and unpleasentness | 1.5 hour testing session |
Neuromodulation to Facilitate the Effect of Ketamine

Study Overview
=================
Brief Summary
-----------------
application of external neuromodulation along with ketamine infusion.

Detailed Description
-----------------
apply TMS concurrent with ketamine infusion in order to increase the likliehood & strength of therapeutic benefit

Official Title
-----------------
Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.

Conditions
-----------------
Depression, Chronic Pain, Substance Abuse

Intervention / Treatment
-----------------
* Other: co-administration of TMS and infused ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronically ill, treatment-resistant Exclusion Criteria: active psychosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic depression and/or pain<br>co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma | Other: co-administration of TMS and infused ketamine<br>* co-administration of TMS and infused ketamine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Assessment of Function in DSM-4R | treat in order to cause remission of disability | up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thalamocortical dysrhythmia, transcranial magnetic stimulation (TMS), transcranial Electrical Stimulation (tES), (N-methyl-D-aspartate) NMDA-R antagonist, ketamine infusion, neuromodulation, synergistic effect, remission
The Impact of Orthopaedic Smoking Cessation Education on Cigarette Abstinence Self-Efficacy: A Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The investigators of this study aim to evaluate the impact of a new orthopaedic related smoking cessation discussion on smoking behavior. Considering the high prevalence of patients who smoke and receive orthopaedic management, we are interested in determining whether an orthopaedic smoking cessation discussion impacts smoking abstinence self-efficacy over time compared to a general smoking cessation discussion.

Conditions
-----------------
Cigarette Smoking

Intervention / Treatment
-----------------
* Behavioral: General Smoking Cessation Discussion
* Behavioral: Orthopaedic Related Smoking Cessation Discussion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Daily cigarette smokers (5 cigarettes or more a day for past year), 18 years of age or older, new orthopaedic management, native English speaker Exclusion Criteria: Patients unable to provide consent, suffer an impairment (mental, psychiatric, hearing or sight), alcohol and illicit drug abusers, homeless, presently managed with a smoking cessation medication or counseling, living with a cigarette smoker, user of other tobacco products

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br> | Behavioral: General Smoking Cessation Discussion<br>* This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.<br>|
| Active Comparator: Intervention<br> | Behavioral: Orthopaedic Related Smoking Cessation Discussion<br>* The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SASEQ | Smoking abstinence Self-Efficacy Questionnaire | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Knowledge and Motivation to Quit | Knowledge and Motivation assessments | less than 20 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Orthopaedic Smoking Cessation Discussion, Smoking Cessation, Randomized Controlled Trial
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Study Overview
=================
Brief Summary
-----------------
Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Detailed Description
-----------------
it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Official Title
-----------------
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Conditions
-----------------
Obese, Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers

Intervention / Treatment
-----------------
* Drug: losartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetic nephropathy CKD at stage 1 4 Exclusion Criteria: Type 1 diabetes or nondiabetic renal disease An elevated plasma K level.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: losartan|losartan, 100mg daily,|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GFR, HbA1c and the adiponectin concentration. |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obese female, Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers, Adiponectin